Repurgenesis Co., LTD. will attend NVIDIA GTC 2026 in San Jose, California, this March, where the company will present our AI-powered drug repurposing technology. As one of the world's premier AI conferences, NVIDIA GTC brings together leading innovators in artificial intelligence, accelerated computing, and life sciences.

At the conference, Repurgenesis will showcase a poster presentation demonstrating how our proprietary AI-driven platform accelerates the discovery of new therapeutic indications for existing drugs.

Poster ID: P81062

The Repurgenesis AI platform integrates multi-modal biomedical data, advanced machine learning algorithms, and high-performance computing to systematically identify novel clinical opportunities for approved or off-patent drugs. By combining AI with drug repurposing strategies, the platform aims to significantly reduce the cost required to bring new therapies to patients.

Repurgenesis is dedicated to advancing next-generation drug discovery through artificial intelligence and strategic drug repurposing. The company continues to develop our integrated AI drug repurposing platform while exploring partnerships with global pharmaceutical and technology companies.